Sepsis, Severe
43
11
11
15
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.0%
3 terminated out of 43 trials
83.3%
-3.2% vs benchmark
7%
3 trials in Phase 3/4
13%
2 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (43)
Bispectral Index (BIS) for Classification of Procalcitonin (PCT) Sepsis Grades in Critically Ill Patients With Sepsis
Sepsis: From Syndrome to Personalized Care
Treatment Strategy of Human Gamma Globulin on the Therapy for Intensively Ill Children With Inflammatory Storm
Role of Transposable Elements in Septic Immune Aging
Early Intravenous Hydrocortisone in Sepsis
Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room
Does the Phoenix Pediatric Sepsis Prognosis Prediction Scale Work
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
LIPIDS-P Trial Phase I/II Trial
Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy
Early Administration of Norepinephrine in Sepsis
Microcirculation Properties of Albumin for Fluid Resuscitation in Septic Shock
Accuracy of Venous Excess Ultrasound (VEXUS) Score Versus Central Venous Pressure in Patients With Severe Sepsis
Health Related Quality of Life After Intensive Care for Sepsis, a National Cohort Study.
The Effect pf Goal-directed De-escalation in ARDS on Organ Function and Mortality
Early Administration of Vitamin C in Patients With Sepsis or Septic Shock in Emergency Departments
Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis
Effect of Probiotics on Cytokines in Sepsis in Children
The Value of Full-targeted Pathogen Capture Metagenomics Next Generation Sequencing in Etiological Diagnosis of Sepsis
High-dose Intravenous Vitamin C in Patients With Septic Shock